CureVac NV

Company Profile

CureVac NV had its IPO on 2020-08-14 under the ticker symbol CVAC.

The company operates in the Healthcare sector and Biotechnology industry. CureVac NV has a staff strength of 904 employees.

Stock update

Shares of CureVac NV opened at $8.44 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $8.09 - $8.49, and closed at $8.12.

This is a -4.25% slip from the previous day's closing price.

A total volume of 310,833 shares were traded at the close of the day’s session.

In the last one week, shares of CureVac NV have slipped by -10.67%.

CureVac NV's Key Ratios

CureVac NV has a market cap of $2.12 billion, indicating a price to book ratio of 2.0711 and a price to sales ratio of 13.2866.

In the last 12-months CureVac NV’s revenue was $67.42 million with a gross profit of $-91549000 and an EBITDA of $-209599008. The EBITDA ratio measures CureVac NV's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, CureVac NV’s operating margin was 0% while its return on assets stood at -14.02% with a return of equity of -40.77%.

In Q1, CureVac NV’s quarterly earnings growth was a positive 0% while revenue growth was a negative 71.6%.

CureVac NV’s PE and PEG Ratio

Forward PE

9.1659

Trailing PE

0

PEG

Its diluted EPS in the last 12-months stands at $-1.49 per share while it has a forward price to earnings multiple of 9.1659 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into CureVac NV’s profitability.

CureVac NV stock is trading at a EV to sales ratio of 8.6122 and a EV to EBITDA ratio of -8.8941. Its price to sales ratio in the trailing 12-months stood at 13.2866.

CureVac NV stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$973.67 million

Total Liabilities

$90.30 million

Operating Cash Flow

$0

Capital Expenditure

$13.16 million

Dividend Payout Ratio

0%

CureVac NV ended 2024 with $973.67 million in total assets and $0 in total liabilities. Its intangible assets were valued at $973.67 million while shareholder equity stood at $713.40 million.

CureVac NV ended 2024 with $0 in deferred long-term liabilities, $90.30 million in other current liabilities, 26862000.00 in common stock, $-1363234000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $617.52 million and cash and short-term investments were $620.59 million. The company’s total short-term debt was $5,058,000 while long-term debt stood at $0.

CureVac NV’s total current assets stands at $686.92 million while long-term investments were $0 and short-term investments were $3.07 million. Its net receivables were $5.84 million compared to accounts payable of $14.97 million and inventory worth $24.68 million.

In 2024, CureVac NV's operating cash flow was $0 while its capital expenditure stood at $13.16 million.

Comparatively, CureVac NV paid $0 in dividends in 2024.

Other key metrics

Current Trading Price

$8.12

52-Week High

$17.21

52-Week Low

$5.63

Analyst Target Price

$16.33

CureVac NV stock is currently trading at $8.12 per share. It touched a 52-week high of $17.21 and a 52-week low of $17.21. Analysts tracking the stock have a 12-month average target price of $16.33.

Its 50-day moving average was $9.18 and 200-day moving average was $8.69 The short ratio stood at 8.25 indicating a short percent outstanding of 0%.

Around 4544.4% of the company’s stock are held by insiders while 2443.9% are held by institutions.